Voquezna (vonoprazan) / Takeda, Otsuka, Phathom Pharma - LARVOL DELTA

Bioequivalence Study to Compare Vonoprazan 20 mg Film Coated Tablets Versus Voquezna® 20 mg (Vonoprazan) Tablets (clinicaltrials.gov) - P1 | N=28 | Completed | Sponsor: Humanis Saglık Anonim Sirketi

New P1 trial • Gastrointestinal Disorder • Infectious Disease

The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients (clinicaltrials.gov) - P1/2 | N=47 | Not yet recruiting | Sponsor: First Affiliated Hospital of Chongqing Medical University

New P1/2 trial • Transplantation

Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (clinicaltrials.gov) - P3 | N=88 | Not yet recruiting | Sponsor: Tanta University

New P3 trial • Infectious Disease

Analysis of infection-related adverse events induced by proton pump inhibitors based on the FAERS and JADER databases. (PubMed, Medicine (Baltimore)) - "In the use of PPIs, we should pay attention to the occurrence of related adverse reactions, especially the damage to the infection-related adverse effects, monitor the relevant indicators, and take timely intervention measures to ensure the safety of medication."

Adverse events • Journal • Gastrointestinal Disorder • Infectious Disease • Pneumonia • Respiratory Diseases

Evaluating the Efficacy of Vonoprazan in Preventing Post-Endoscopic Variceal Band Ligation Ulcers: A Randomized Controlled Trial (clinicaltrials.gov) - P2 | N=154 | Not yet recruiting | Sponsor: King Edward Medical University

New P2 trial • Liver Cirrhosis

Randomized Comparison of Vonoprazan-Amoxicillin Dual Therapy Versus Bismuth Quadruple Therapies for Helicobacter pylori Eradication: A Multicenter Trial Evaluating National Centralized Drug Procurement Antibiotics. (PubMed, J Gastroenterol Hepatol) - "This study confirms that 10-day vonoprazan-amoxicillin dual therapy (using National Centralized Drug Procurement antibiotics) demonstrates noninferior efficacy to bismuth quadruple therapy while offering superior safety, better compliance, and the advantage of shorter treatment duration. These findings support its adoption as a first-line regimen for large-scale H. pylori eradication programs."

Journal • Infectious Disease

Effect of Vonoprazan, potassium-competitive acid blocker, on Atezolizumab plus Bevacizumab efficacy in patients with hepatocellular carcinoma: a multicenter retrospective study. (PubMed, Int J Clin Oncol) - "Vonoprazan was not associated with worse PFS and OS in patients with HCC treated with Atz/Bev than in those who did not receive PPIs and neither."

Journal • Retrospective data • Genito-urinary Cancer • Hepatocellular Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

Smartphone-assisted HPTLC for simultaneous determination of vonoprazan fumarate and aspirin: a comparative study with HPTLC densitometry. (PubMed, Sci Rep) - "Statistical comparison with a reported HPLC method confirmed the reliability of the proposed approaches. Notably, the smartphone-assisted HPTLC/Image J method offers a cost-effective, accessible, and sustainable alternative to conventional HPTLC densitometry, while maintaining comparable accuracy and precision, making it a promising tool for routine pharmaceutical analysis."

Journal

Exploratory Study on Efficacy and Safety of Minocycline-Based Dual Therapy for Helicobacter pylori Eradication. (PubMed, Pathogens) - "VM dual therapy was shown to be an effective and safe treatment option, demonstrating comparable eradication rates to VA dual therapy. While VM had a slightly higher incidence of AEs, they were generally mild and manageable. VM remained a valuable alternative for patients with penicillin allergies or amoxicillin resistance."

Clinical • Journal • Allergy • Immunology • Infectious Disease

Efficacy of Vonoprazan in Nonsteroidal Anti-Inflammatory Drug-Induced Ulcer in Terms of Ulcer Recurrence and Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. (PubMed, Gastroenterol Res Pract) - "The GRADE of evidence was moderate. Vonoprazan could significantly reduce the risk of ulcer recurrence and gastrointestinal bleeding as compared to lansoprazole in patients with NSAID-induced ulcers."

Journal • Retrospective data • Review • Gastroenterology • GAST • PGC

Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV. (PubMed, J Infect Dis) - P=N/A | "VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety."

Journal • Fatigue • Human Immunodeficiency Virus • Infectious Disease • Pain

Successful Treatment of Refractory Helicobacter pylori Infection with a Potassium-Competitive Acid Blocker-Based Regimen: A Case Report. (PubMed, Int J Infect Dis) - "The patient was treated with a salvage regimen consisting of vonoprazan, a potassium-competitive acid blocker (PCAB), and amoxicillin, which successfully eradicated the infection. The failure of prior regimens was likely due to inadequate acid suppression, which may be linked to the metabolism of first-generation proton pump inhibitors (PPIs). This case highlights the potential of PCAB-based therapy in refractory H. pylori infections and emphasizes the importance of acid suppression for successful eradication."

Journal • Dyspepsia • Gastric Adenocarcinoma • Gastric Cancer • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Oncology • Peptic Ulcer • Solid Tumor

JSHERO4: 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy (clinicaltrials.gov) - P4 | N=316 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P4 trial • Infectious Disease

Gastroesophageal reflux disease: comprehensive review from medical to surgical management. (PubMed, Int J Surg) - "gastroesophageal reflux disease is a heterogeneous, multifaceted disease requiring a tailored approach. Initial management prioritizes lifestyle measures and empiric acid suppression. Diagnostic evaluation refines treatment in non-responders or complicated cases. Effective long-term control may require surgery or endoscopic intervention, particularly for patients with refractory symptoms, hiatal hernia, or concerns over chronic proton pump inhibitor use. Further research is needed to establish long-term efficacy and optimal patient selection for advanced therapies."

Journal • Gastroenterology • Gastroesophageal Reflux Disease

Vonoprazan attenuates proteinuria in diabetic kidney disease through potential direct renal mechanism. (PubMed, Sci Rep) - "Additionally, vonoprazan-treated patients showed significant improvement in eGFR after 3 months compared to baseline levels (p < 0.05), with this improvement being superior to that observed with lansoprazole (p < 0.05). Vonoprazan may have a direct renal effect, warranting further research to elucidate its mechanism in reducing albuminuria."

Clinical • Journal • Diabetes • Diabetic Nephropathy • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

In vivo and in silico assays demonstrate that the hydroalcoholic extract of Aloysia polystachya and carvone promote anti-ulcer effects. (PubMed, J Ethnopharmacol) - "The findings of this study demonstrate that the hydroalcoholic extract of A. polystachya (HEAp) and its bioactive compound carvone possess significant gastroprotective and gastric healing properties. These effects are likely mediated through the modulation of sulfhydryl compounds, anti-inflammatory and antioxidant defenses, and antisecretory mechanisms. The identification of phenolic constituents, combined with in silico analyses, further supports the potential therapeutic relevance of HEAp and carvone. Collectively, these results highlight that the phytoconstituents from A. polystachya corroborate the traditional use of the plant and are promising candidates for the investigation of anti-ulcer gastric agents."

Journal • Preclinical • Peptic Ulcer • MPO

Class effects of proton pump inhibitors in preventing oxaliplatin-induced peripheral neurotoxicity. (PubMed, J Pharmacol Sci) - "Basic research has revealed that omeprazole, a proton pump inhibitor (PPI), exerts preventive effects against OIPN...Notably, esomeprazole, lansoprazole, and rabeprazole, classified as PPIs, prevented oxaliplatin-induced cultured F11 neuronal cell damage, and repeated PPI administration prevented mechanical allodynia in rats. However, vonoprazan, a potassium ion-competitive acid blocker, did not exert such effects. Overall, our results highlight the class effects of PPIs against OIPN."

Journal • Pain

Awareness, attitudes, and clinical utilization of vonoprazan for Helicobacter pylori infection and gastroesophageal reflux disease among Chinese physicians: a nationwide cross-sectional study. (PubMed, BMC Gastroenterol) - "In this national sample, Chinese physicians demonstrated moderate awareness but limited real-world use of vonoprazan for H. pylori infection and GERD. Utilization was largely confined to tertiary centers and gastroenterology specialists. Broader educational initiatives, inclusion in hospital formularies, reimbursement alignment, and generation of real-world evidence may help facilitate appropriate and equitable adoption of vonoprazan in clinical practice."

Journal • Observational data • Gastroenterology • Gastroesophageal Reflux Disease • Infectious Disease

Vonoprazan- making a case for Functional Dyspepsia. (PubMed, J Pak Med Assoc) - No abstract available

Journal • Dyspepsia

TV-HP: Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication (clinicaltrials.gov) - P2/3 | N=240 | Recruiting | Sponsor: First People's Hospital of Hangzhou

Head-to-Head • New P2/3 trial • Infectious Disease

Symptom Relief With Vonoprazan Treatment in Gastroesophageal Reflux Disease Patients With Diabetes in China: Post Hoc Analysis of the VIEW Study (ISPOR-EU 2025) - P=N/A | "This study demonstrated effective symptom relief with vonoprazan treatment in GERD patients with diabetes."

Clinical • Retrospective data • Diabetes • Gastroenterology • Gastroesophageal Reflux Disease • Metabolic Disorders

Economic and Antibiotic Benefits of Vonoprazan-Based Regimens for First-Line Helicobacter Pylori Eradication in China (ISPOR-EU 2025) - "OBJECTIVES: To evaluate the economic and antibiotic stewardship impact of vonoprazan-based regimens (bismuth quadruple [VPZ-BQT] and dual therapy [vonoprazan with high-dose amoxicillin, VPZ-HDT]) versus proton pump inhibitor-bismuth quadruple (PPI-BQT) for first-line H. pylori eradication in China, given rising antibiotic resistance and suboptimal PPI therapies. An epidemiological estimation of the Chinese H. pylori-infected patient population, coupled with a decision-tree model, was conducted to compare the antibiotic utilization of VPZ-BQT and VPZ-HDT versus PPI-BQT across two 14-day treatment courses. VPZ-based regimens, particularly VPZ-HDT, offer notable antibiotic stewardship and economic advantages for H. pylori eradication in China, with VPZ's superior efficacy driving these positive outcomes. Strategic adoption of effective VPZ-based therapies may optimize antibiotic stewardship and support national resistance control efforts."

Clinical • Infectious Disease

Effectiveness of Vonoprazan on Health-Related Quality of Life and Sleep Quality in Chinese Patients With Reflux Esophagitis: Post Hoc Analysis of the VIEW Study (ISPOR-EU 2025) - P=N/A | "Vonoprazan treatment in real-world clinical practice improved HRQoL and sleep quality among Chinese patients with RE."

Clinical • HEOR • Retrospective data • CNS Disorders • Depression • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Mood Disorders • Psychiatry

Efficacy of Potassium-Competitive Acid Blockers in Functional Dyspepsia: A Systematic Review and Meta-Analysis. (PubMed, Gastroenterology Res) - "Potassium-competitive acid blockers (PCABs), such as vonoprazan and tegoprazan, provide rapid and sustained gastric acid inhibition and may represent a therapeutic alternative. PCABs show promise as a potential therapeutic option in FD, particularly in patients who do not respond to or cannot tolerate proton pump inhibitors. Further placebo-controlled trials are needed to confirm efficacy and define long-term outcomes."

Journal • Retrospective data • Dyspepsia • Gastroenterology • Gastrointestinal Disorder

Updated treatment options for gastroesophageal reflux disease in children: practical guide for clinician. (PubMed, Expert Opin Pharmacother) - "Pharmacotherapy is summarized with emphasis on efficacy and safety: proton-pump inhibitors for documented esophagitis in children ≥1 year; H2-receptor antagonists for short-term or step-down use; alginates for post-prandial symptoms or mild disease; emerging potassium-competitive acid blockers under pediatric evaluation; and selective prokinetics/baclofen in refractory, dysmotility-predominant cases...An age-aware, stepwise strategy - non-pharmacologic first, time-limited proton pumb inhibitors with planned step-down, and cautious adjuncts - optimizes outcomes while minimizing harm. Priorities include pediatric trials for potassium-competitive acid blockers (P-CABs) and alginates, validated deprescribing pathways, noninvasive biomarkers, and scalable care models."

Journal • Review • Allergy • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Pediatrics